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Summary 
Mycosisfungoides  (MF) is a rare form of cutaneous T  cell lymphoma suspected of having a viral 
etiology. As in adult T  cell leukemia,  the virus involved may be human T  lymphotropic virus 
type 1 (HTLV-1). We cultured the peripheral blood mononuclear cells (PBMC) of 29 patients 
with MF HTLV-1 seronegative by enzyme-linked immunosorbent assay and Western blot. The 
presence of reverse transcriptase (RT) and p24 antigen was investigated in the concentrate supematant 
of the culture.  The DNA of all  studied patients was submitted to polymerase chain reaction 
and Southern blot analysis  using primers and probes recognizing the tax region of HTLV-1/2 
and the pol region of HTLV-1.  10 of 29 patients were found positive to HTLV-1, whereas they 
were always negative to RT and p24.  The  same results were confirmed in double blind after 
6 too. Our findings suggest HTLV-1 may be involved in the etiology of MF, at least in certain cases. 
C 
utaneous T cell lymphomas (CTCLs) are rare neoplastic 
disorders of CD4 §  4B4 § (helper/memory) T cells, in- 
cluding adult T cell leukemia/lymphoma (ATL), mycosis fun- 
goides (MF) and its leukemic variant,  the Sezary syndrome 
(SS) (1). ATL is an aggresive disorder causally associated with 
HTLV-1 infection (2-4). High incidences of ATL have been 
reported in Japan,  the Caribbean,  and parts of Eastern Eu- 
rope where HTLV-1 is endemic (5, 6). Most if not all pa- 
tients with ATL are HTLV-1 seropositive (7). T  cells from 
patients with ATL express receptors for IL-2 (Tac +) and are 
predominantly  CD4 §  whereas  the  leukemic  cells  of MF 
and SS are CD4 + and Tac-. In the etiology ofMF, HTLV-1 
is implicated.  Hall first described an association of deleted 
HTLV-1 provirus  and MF in  seronegative patients  (8,  9); 
Zucker et al. (10) detected human T lymphotropic viruslike 
particles in cultures of PBL from patients with MF.  Sahai 
et al. (11) found that 4 of 27 patients with MF and SS were 
infected with HTLV-1, whereas Wittacher and Luzzatto (12) 
found defective HTLV-1 sequences in only 10% of patients 
with MF. Moreover, Bazarbachi et al. (13) found no HTLV-1 
infection markers in 24 cases of French and Portuguese pa- 
tients with MF and SS, and more recently Pancake and Zucker 
(14) detected HTLV-related tax sequences in a large number 
of patients  with  MF. 
In light of these data, we analyzed genomic DNA isolated 
from mononuclear cells, using the PCR method, with primers 
flanking HTLV-1/2 tax and HTLV-Ipol sequences in 29 Italian 
patients with MF. The patients were HTLV-1 seronegative 
in both ELISA and Western blot (WB) assay. As control, 
PCR was used to detect the presence of HTLV-1 sequences 
in DNA prepared from cultured blood mononuclear cells ob- 
tained from 20 healthy blood donors. 
Materials and Methods 
Patients.  We studied 29 patients (Table 1). All patients, except 
the one who received intravenous chemotherapy, either received 
topical applications of steroids, UV irradiation (PUVA) or IFN-ct 
at the time the specimens were obtained. Their ages ranged from 
28 to 89 yr. All the patients  were Italian,  from HTLV-l-nonen- 
demic areas, with no family history of neurological disease or per- 
sonal history  of drug abuse, blood transfusion,  or contact  with 
people from Asia or Africa. All patients were seronegative to HTLV- 
1/2 antibodies by ELISA and WB. As a negative control, 20 healthy 
blood donors were studied. 
Cell Culture.  PBMC were  isolated  by Lymphoprep  (Ficoll- 
Hypaque)  density  gradient  centrifugation,  washed  three  times 
in PBS (Oxoid, Basingstoke, UK), and cultured at a density of 106 
per ml in RPMI-1640 medium (GIBCO BRL, Gaithersburg, MD) 
supplemented with 20% FCS serum (GIBCO BRL), antibiotics, 
0.2 mg/ml PHA, and 10% IL-2 (Pan-Data Systems, Inc.,  Kock- 
ville, MD). 
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Duration  Blood 
Patient  Sex/age  of disease  Therapy  transfusion  TNM stage 
Z.B.  M/46  6 yr  PUVA  No  I  A  (Tt  NOM0) 
B.G.  M/79  5 yr  PUVA  No  I  A  (T1  NOM0) 
M.O.  F/54  6 yr  PUVA  +  IFN-oe  No  I A  (T1 NOM0) 
B.B.  F/57  5 yr  PUVA  No  I  A  (T1 NOM0) 
B.G.  M/65  8 yr  Steriod  No  I A  (T1 NOM0) 
V.R.  M/36  3 yr  PUVA  No  I A  (T1 NOM0) 
A.G.  F/74  5 yr  PUVA  No  I  A  (T1 NOM0) 
M.P.  F/58  3 yr  PUVA  No  I  A  (T1 NOM0) 
C.V.  M/53  1 yr  PUVA  No  I A  (T1 NOM0) 
S.M.  M/57  15  yr  PUVA  Yes  I  A  (T1 NOM0) 
S.A.  M/53  1 yr  PUVA  No  I  A  (T1 NOM0) 
S.A.  M/55  3  mo  PUVA  No  I  A  (T1  NOM0) 
D.P.  M/62  1 yr  PUVA  No  I  A  (T1 NOM0) 
B.M.  F/70  1 yr  PUVA  +  IFN-oe  No  I  B (T2 bNOM0) 
P.E.  F/44  2 yr  PUVA  +  IFN-ot  No  I  B (Tz NOM0) 
Z.E.  M/53  1 yr  PUVA  +  IFN-o~  No  I  B  (Tz NOM0) 
M.G.  M/57  2 yr  Radiotherapy  No  I  B  (Tz bN1M0) 
F.C.  M/45  1 yr  PUVA  +  IFN-c~  No  I B  (T2 NOM0) 
B.F.  M/44  1 yr  PUVA  +  IFN-c~  No  I  B  (Tz NOM0) 
A.N.  M/70  2 yr  PUVA  +  IFN-cz  No  I B  (T2 NOM0) 
G.C.  M/28  3 yr  PUVA  No  I  B (T2 NOM0) 
B.B.  M/45  7 yr  IFN-ol  No  I  B  (T2 aNOM0) 
F.G.  M/72  1 yr  PUVA  No  I  B (T2 NOM0) 
P.F.  F/58  1 yr  PUVA  +  IFN-cz  No  II A  (T2 bNIM0) 
B.P.  M/70  2 yr  Chemotherapy  No  II B (T3 NOM0) 
G.B.  M/68  2 yr  PUVA  +  IFN-ot  No  III (T4 NOM0) 
G.B.  M/85  10 yr  PUVA  No  III (T4 NOM0) 
C.  P-,.  M/61  7 yr  PUVA  No  III (T4 NOM0) 
P.B.  M/78  5 yr  PUVA  No  III (T4 NOM0) 
DNA Purification, PCR, and Southern Blot Analysis for HTLV-1. 
DNA was isolated by overnight incubation of PBMC at 37~  in 
lysis buffer (100 mM NaC1, 10 mM Tris-HC1, pH 8, 25 mM EDTA, 
and 0.5% SDS) containing 100 ktg/ml proteinase K. After phenol 
chloroform extraction, the DNA was precipitated with ethanol and 
redissolved  in sterile H20. DNA concentration was estimated by 
absorption at 260 nm. 
Amplification was carried out in a total volume of 100 #1 using 
buffer,  deoxynucleotides,  MgC12,  and  taq  polymerase  (Perkin 
Elmer Cetus, Norwalk, CT). Reaction mixtures contained 25 pmol 
of each primer,  1/~g genomic DNA,  and 2.5  U  taq polymerase. 
Samples were denaturated in a DNA thermal cycler (Perkin Elmer 
Cetus)  for  2  rain  at  95~  and  then  subjected  to  35  cycles of 
amplification. Each cycle consisted of a denaturating phase of 95~ 
for 1 rain, primer annealing at 58~  for 1 rain, and chain elonga- 
tion at 72~  for i  rain. DNA samples from normal blood donors 
were used as negative controls. As a positive control, DNA from 
HTLV-l-infected cells (MT2)  was used (kindly provided by Drs. 
R.C. Gallo and M.G. Sarngadharan, National Institutes of Health, 
Bethesda, MD).  Oligonucleotide primers used were: SK 43 and 
SK 44, designed to amplify a 159-bp fragment of DNA from the 
tax region of both the HTLV-1 and HTLV-2 genomes, SK 54 and 
SK 55, designed to amplify a 119-bp fragment of DNA from the 
pol region of the HTLV-1  genome (Perkin Elmer Cetus). 
20 #1 of each amplified sample was run on 0.8%  agarose gel 
in TBE (0.089 M  Trisborate, 0.089  M  boric acid,  and 0.002  M 
EDTA) and blotted into a nylon membrane (Amersham Interna- 
tional,  Amersham,  Bucks,  UK)  by standard  Southern  method 
(Maniatis et al.) (15). 
Hybridization was performed with rapid hyb-buffer (Amersham 
International) for 2 h at 42~  with probes SK 45 or SK 56 (Perkin 
Elmer Cetus). 
20 pmol of probes were labeled at 3' OH ends with dUTpobiotin 
in a tailing reaction, using the enzyme terminal transferase. 
The membranes were then washed for 20 rain in 5x  SSC, 0.1% 
(wt/vol) SDS at room temperature, and twice for 15 min in 0.1  x 
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acids hybridized with the biotinylated probes, we used the Polar 
Plex Chemiluminescent blotting Kit  |  (Millipore Corp., Bedford, 
MA) according to product  specifications. 
PCR  for the Detection of  EBV Genome.  The primer pair (primers 
ebvP1 and ebvP2) specific for the 405-bp region was generated from 
the drip region of the EBV genome. These primers have been de- 
scribed  by Glukhov et al.  (16). 
To perform "nested" PCR, two sets of primers were used; both 
are located in  the BamHI-W region  of the EBV  genome.  The 
BamHIoW region is repeated up to 11 times within the genome. 
The sequences of the primers were: (a) "outer" primers ebvP3 (5'- 
GGGTGAGGCCCAGCCCCTC-3',  positions  from  13.822  to 
13.841) and ebvP4 (5'-CATTTGTGTGGACTCCTGGC-3', posi- 
tion from 14.411 to 14.392);  and (b) "inner" primers ebvP5  (5'- 
GGAAGCGGGTCTATGGTTGG-3',  positions  from  14.138 to 
14.157) and ebvP6 (5'-GTCCCCCTCCCTAGAACTGA-3', posi- 
tions from 14.339  to 14.320).  PCIL amplification products were 
590 and 202 bp in length for outer and inner primers, respectively. 
All oligonucleotides were synthesized on an automated DNA 
synthesizer (model 380A;  Applied Biosystems,  Inc., Foster City, 
CA) using the phosphoramidite method. 
Nested PCR was carried out in two steps. Both steps were per- 
formed in a final volume of 50/zl containing 67 mM Tris-HC1, 
pH  8.8,  16.6  mM  (NH4)2 SO4,  1.5  mM MgC12, 2.5  U  Biotaq 
polymerase (Biomaster Co.,  Moscow,  Russia),  200 /~M of each 
dNTP, 15 pmol of  each primer, and 0.18/~g (DNA from the B95-8 
cell line,  EBV-positive control DNA)  or 0.5 #g genomic DNA. 
The mixture was subjected to PCR amplification using a DNA 
thermal cycler (Perkin  Elmer Cetus).  The first  step  consisted  of 
35 cycles of denaturation at 94~  for 1 min (3 min for the first 
cycle); annealing of primers at 56~  for I rain (2 min for the first 
cycle); extension at 72~  for 2 rain (3 min for the first cycle and 
5 min for the last cycle), and was performed with outer primers 
ebvP3  and ebvP4.  PCIL conditions for primers ebvPl and ebvP2 
were identical. 
In the second step, 1/zl (1:100 diluted) of the first PCR products 
was amplified,  using the same protocol, with inner primers ebvP5 
and ebvP6,  for another 25 cycles. 
5 #1 of PCR reactions was resolved on a 1.5% agarose gel, con- 
taining 0.5/~g/ml ethydium bromide and electrophoresed in TBE 
buffer. The bands were visualized with UV illumination and pho- 
tographed. 
As positive controls for PCR analysis, we chose the B95-8 cell 
line,  which is an EBV-positive  Marmoset cell line. 
Results and Discussion 
PBMC  from  all  patients  were  cultured  as  reported  in 
Materials and Methods.  After 15 d of culture, the cells were 
Figure  1.  Amplification  of HTLV-1/2  target sequences  in DNA samples 
from the cultured lymphocytes  of  the patients with MF. The DNA samples 
were amplified  by PCR and by Southern blot analyzed  with primers SK 
43-SK 44 recognizing  tax region of HTLV-1/2  and hybridyzed  with probe 
SK 45 as described in Materials and Methods. (Lanes 1-10) Patients with 
MF.  (K-) Negative control was genomic DNA from lymphocytes of 
healthy blood donors. (K +) Positive control was genomic DNA from 
HTLV-1 producer cell line MT 2. 
harvested and their DNA extracted. PCR was used to detect 
HTLV-1 DNA in these samples using the conditions, primers, 
and  probes  described in  Materials  and  Methods. 
The results  show  that  10  of 29  patients  with  MF  were 
positive to the tax  region  of the  HTLV-1/2 genome  (Fig. 
1) and that  the same patients  were also positive to the pol 
region  of the  HTLV-1  genome  (Fig.  2). 
Five lines  proliferated  spontaneously  and  grew  in  large 
clumps.  Comparative phenotypic analysis  showed them  to 
be predominantly B cells. EBV is one of the viruses that is 
capable of immortalizing B lymphocytes (17,  18). The cells 
were shown to be EBV infected by PCR analysis with driP 
(ebvP1/ebvP2)  and  BamHI-W  (ebvP3/ebvP4  and  ebvP5/ 
ebvP6) primers (Fig. 3, A  and B). In addition,  one cell line 
from the patients with MF was not immortalized, but it was 
shown to be positive to the EBV genome by PCR (Fig. 3, 
patient  6). 
Our results also showed two patients  with concomitant 
sequences of HTLV-1 and EBV in B cells. The detection of 
HTLV-1 and EBV DNA in cell lines from patients with MF 
is summarized  in Table 2.  This last  finding is not unusual 
in patients with ATL (19, 20), or in those with MF as found 
by Hall et al.  (8). Additionally, EBV is expressed in a large 
number  of conditions  (21-23). 
Our results demonstrate a high incidence of HTLV-1 tax 
and pol genes integrated into  the DNA  of peripheral lym- 
phocytes of MF  patients.  No  significant  level of Mg +-  or 
Mn +-dependent RT was detected in the concentrate super- 
natant fluid of cultures,  so no evidence was found of infec- 
Figure 2.  Amplification of HTLV-1 target sequences in 
DNA samples from the cultured lymphocytes  of the patients 
with MF. The DNA samples were by PCR and by Southern 
blot analyzed  with primers SK 54 and SK 55 recognizing the 
pol region of HTLV-1 and hybridzed with probe SK 56 as 
described  in Materials and Methods. (Lanes  I-I0) Patients with 
MF. (K-) Negative control was genomic DNA from lym- 
phocytes of healthy blood donors. (K +) Positive  control was 
genomic DNA from HTLV-1 producer cell line MT 2. 
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antigen test for HTLV-1 was also negative as well (data not 
shown). 
As  the  incidence of HTLV-1  in  northern  Italy,  where 
HTLV-1 is not considered endemic, was found to be very 
high, after 6 mo we took blood from the same patients and 
cultivated lymphocytes in double-blind experiments to re- 
Figure  3.  Amplification  of  EBV target sequences  in DNA samples from 
the cultured lymphocytes  of the patients with MF (A and B). (A and B) 
Yield of  PCR products  after  amplification  of strongly  EBV-positive  DNA 
samples. The DNA samples were amplified by PCP, (as described in 
Materials and Methods) with EBV primer pairs: ebvP1/P2 (lanes 1, A 
and B) specific  for the ori P-region  of  EBV, nested  primer  pairs: ebvP3/ebvP4 
(lanes 2, A and B) and ebvP5/ebvP6  (lanes 3, A and B) specific  for the 
Bam HI-W region of EBV. Positive control was genomic DNA from 
'~27,000 cells) from the EBV-producer  cell line B95-8 (K  + in A and B). 
Negative controls (genomic DNA from the H9 cell line was also used 
(K- in A and B). 
Table  2.  HTLV-1/EBV  Detection in Patients with Mycosis Fungoides 
Duration  BamHI-W 
Patient  Sex/age  of disease  orlP  (590 bp) 
PCR 
BamHI-W  Tax  Pol 
(202 bp)  HTLV1-2  HTLV1  TNM stage 
Z.B.  M/46  6 yr  Neg.  Neg.  Neg.  Pos.  Pos. 
B.G.  M/79  5 yr  Neg.  Neg.  Neg.  Neg.  Neg. 
M.O.  F/54  6 yr  Neg.  Neg.  Neg.  Pos.  Pos. 
B.B.  F/57  5 yr  Neg.  Neg.  Neg.  Pos.  Pos. 
B.G.  M/65  8 yr  Pos.  Pos.  Pos.  Pos.  Pos. 
V.  R,.  M/36  3 yr  Neg.  Neg.  Neg.  Neg.  Neg. 
A.G.  F/74  5 yr  Neg.  Neg.  Neg.  Neg.  Neg. 
M.P.  F/58  3 yr  Pos.  Pos.  Pos.  Neg.  Neg. 
C.V.  M/53  1 yr  Pos.  Pos.  Pos.  Neg.  Neg. 
S.M.  M/57  15 yr  Pos.  Pos.  Pos.  Neg.  Neg. 
S.A.  M/53  1 yr  Pos.  Pos.  Pos.  Neg.  Neg. 
S.A.  M/55  3 mo  Pos.  Pos.  Pos.  Pos.  Pos. 
D.P.  M/62  1 yr  Neg.  Neg.  Neg.  Pos.  Pos. 
B.M.  F/70  1 yr  Pos.  Pos.  Pos.  Neg.  Neg. 
P.E.  F/44  2 yr  Neg.  Neg.  Neg.  Neg.  Neg. 
Z.E.  M/53  1 yr  Neg.  Neg.  Neg.  Pos.  Pos. 
M.G.  M/57  2 yr  Neg.  Neg.  Neg.  Pos.  Pos. 
F.C.  M/45  1 yr  Neg.  Neg.  Neg.  Neg.  Neg. 
B.F.  M/44  1 yr  Neg.  Neg.  Neg.  Neg.  Neg. 
A.N.  M/70  2 yr  Neg.  Neg.  Neg.  Neg.  Neg. 
G.C.  M/28  3 yr  Neg.  Neg.  Neg.  Neg.  Neg. 
B.B.  M/45  7 yr  Neg.  Neg.  Neg.  Neg.  Neg. 
F.G.  M/72  1 yr  Neg.  Neg.  Neg.  Neg.  Neg. 
P.F.  F/58  1 yr  Neg.  Neg.  Neg.  Pos.  Pos. 
B.P.  M/70  2 yr  Neg.  Neg.  Neg.  Neg.  Neg. 
G.B.  M/68  2 yr  Pos.  Pos.  Pos.  Neg.  Neg. 
G.B.  M/85  10 yr  Neg.  Neg.  Neg.  Neg.  Neg. 
C.R..  M/61  7 yr  Pos.  Pos.  Pos.  Neg.  Neg. 
P.B.  M/78  5 yr  Neg.  Neg.  Neg.  Pos.  Pos. 
I A  (T~ NOM0) 
I A  (T~  NOM0) 
I A  (T~ NOM0) 
I A  (Tt  NOM0) 
I A  (T~ NOM0) 
I A  (T~ NOM0) 
I A  (T~ NOM0) 
I A  (T~ NOM0) 
I A  (T~ NOM0) 
I A  (T~ NOM0) 
I A (T~ NOM0) 
I A  (Tt  NOM0) 
I A  (T~  NOM0) 
I B (T2 bNOM0) 
I B  (T2 NOM0) 
I B  (T2 NOM0) 
I B (T2 bN1M0) 
I B  (T2 NOM0) 
I B  (T2 NOM0) 
I B  (T~ NOM0) 
I B  (T2 NOM0) 
I B (T2 aNOM0) 
I B  (T2 NOM0) 
II A  (Tz bN1M0) 
II B (T3 NOM0) 
Ill (T4 NOM0) 
III (T4 NOM0) 
III (T4 NOM0) 
Ill (T4 NOM0) 
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and to detect specific antibodies by ELISA and WB. HTLV-1 
sequences were researched using the same primers and probes 
and the previous results were confirmed. Our data are in line 
with Hall's findings (8) and show a higher rate of HTLV-1 
than that reported by Wittacher and Luzzatto, (12). Our data 
also show a lower incidence of HTLV tax gene sequences than 
reported by Pancake and Zucker (14). However, our data differ 
from those of Bazarbachi et al.  (13) who found no specific 
HTLV-1 sequences in the cells of patients with MF and SS. 
In addition, even under the same cell culture conditions and 
using PCR, we never found any HTLV-1 sequences in the 
lymphocytes of the 20 healthy blood donors. It is interesting 
to note that  the seronegativity described by other authors 
(8,  12,  14), persisted in all our patients, although HTLV-1 
sequences were documented. Our findings may be explained 
by the fact that the virus in patients with MF has  one or 
more deletions, as clearly documented by Hall (8), which 
may  limit  or  prevent  virus  replication,  thus  avoiding  or 
reducing antibody response. 
This last hypothesis requires further documentation, as 6 mo 
later no patient showed signs of serum conversion but all re- 
mained seronegative. Virus deletion may explain the absence 
of RT and of p24 antigen in the supernatant of all the samples 
of cultured lymphocytes, although their search was performed 
every week for 50-60 d and the presence of tax and pol gene 
sequences was always positive in the same cell cultures, thus 
indicating that  the virus was  not  in its replicative phase. 
In conclusion, our results show a high incidence of the 
HTLV-1 sequences in a large number of patients with MF. 
This finding seems to be significant because it was confirmed 
6 mo later in double-blind experiments in the same patients 
whereas no HTLV-l-positive culture was present in the lab- 
oratory, thus, ruling out the possibility of contamination as 
a cause of our positive results. 
Another element which confirms the high significance of 
our data is that all the patients studied came from countries 
where HTLV-1 is not endemic, and they were not at risk 
for HTLV-1 infection. 
This last  fact suggests the possible role of HTLV-1 (or 
deleted HTLV-1) or of a related virus as the cause of certain 
cases of MF. It would be useful, from the onset of the first 
lesions,  to  monitor the patients  with  serological reaction 
(generally patients with MF are seronegative with commer- 
cially available reagents) but also to grow lymphocytes, for 
the detection of RT and p24 in the supernatant and espe- 
cially of HTLV gene sequences in DNA so as to understand 
more clearly the relationship between HTLV-1 and MF. 
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